Bank of America
CURX

Bank of America’s Curanex Pharmaceuticals CURX Stock Holding History

Bank of America’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34
Closed -$11 – 7260
2025
Q4 		$11 Buy
+34
New +$19 ﹤0.01% 7195

Other funds holding CURX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America's CURX Position: Q1 2026 in Review

Bank of America sold out of Curanex Pharmaceuticals (CURX) in Q1 2026, closing a stake of 34 shares — an estimated $11 sold.

Bank of America first reported a position in CURX in Q4 2025 and held it in 1 quarter. The position peaked at $11 in Q4 2025. 8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

  • Bank of America reported no remaining Curanex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 34 Curanex Pharmaceuticals shares in Q1 2026, an estimated $11.
  • Bank of America first reported a position in Curanex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Bank of America's Curanex Pharmaceuticals position peaked at $11 in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.